MiniMed Group (MMED) Fair Value & Analysis
Healthcare · US · Market cap $4.3B
MiniMed Group
MMED · US
Fair value as of: Jul 16, 2026
From 6 valuation models · updated today
Fair value updated Jul 16, 2026 — revised from $0.2500 to $3.69 (+1,376.0%) since Jun 25, 2026. Share price +2.8% over the past month.
Price vs Fair Value (4 months)
4‑month range $10.80 – $20.00 · fair‑value band $2.90 – $4.47 · the $15.42 price screens above the $3.69 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
MiniMed Group (MMED) currently trades at $15.42, while our model-based Fair Value estimate is $3.69 — implying the stock looks roughly 76.1% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, MiniMed Group generated revenue of $3.0B at a net margin of -10.7%. Revenue grew 15.0% year over year. The balance sheet holds a net cash position of $153M. Fundamentals as of Jul 16, 2026
Our scenario range runs from $2.90 (bear case) to $4.47 (bull case); at $15.42, the current price sits above that range. The share trades about 25% below its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -16% fair-value upside — at -76%, MMED screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.
Revenue & earnings trend
FY2023 – FY2026 · reported fiscal years
MiniMed Group reported revenue of $3.1B in FY2026 versus $2.2B in FY2023, a compound +11.4%/yr. Reported net income was −$331M in FY2026.
Is MMED fairly valued? → Check now
Recent news
- MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
- MiniMed Launches Abbott's Instinct Sensors Across European Markets
- This Undervalued Medical-Devices Stock Is Poised for a Rebound
- MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $36.54 | $30.66 | -16% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | CHF 53.28 | CHF 46.31 | -13% |
| ResMed Inc RMD | $193.57 | $187.89 | -3% |
| West Pharmaceutical Services, Inc WST | $329.71 | $137.28 | -58% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MiniMed Group (MMED) undervalued?
What is the fair value of MMED?
What is the quality score of MMED?
What is the revenue of MiniMed Group (MMED)?
What is the net profit margin of MMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full MiniMed Group analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.